Rhumbline Advisers Design Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 53,067 shares of DSGN stock, worth $282,847. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,067
Previous 52,452
1.17%
Holding current value
$282,847
Previous $211,000
16.11%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding DSGN
# of Institutions
98Shares Held
31.9MCall Options Held
1.1KPut Options Held
21.3K-
Sr One Capital Management, LP6.53MShares$34.8 Million9.6% of portfolio
-
Logos Global Management LP San Francisco, CA5.03MShares$26.8 Million1.58% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$12.3 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.7MShares$9.04 Million0.08% of portfolio
-
Tang Capital Management LLC San Diego, CA1.48MShares$7.89 Million0.61% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $297M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...